Rheumatoid arthritis is a debilitating autoimmune disorder marked by persistent inflammation primarily in synovial joints, leading to cartilage breakdown, bone erosion, and severe morbidity. Key players in RA are the fibroblast-like synoviocytes, which become aberrantly activated and aggressively proliferate within the synovium, fueling inflammation and joint damage. Previous research has established that these FLSs exhibit a metabolic shift towards glycolysis—a process by which glucose is fermented to support energy requirements even in oxygen-rich conditions, reminiscent of the Warburg effect observed in cancer cells. However, the upstream regulators driving this metabolic rewiring in RA have remained elusive until now.

The latest findings highlight USP5 as a pivotal molecular switch that facilitates the metabolic reprogramming of FLSs. USP5 is a deubiquitinating enzyme known for its role in removing ubiquitin moieties from specific substrate proteins, thus preventing their proteasomal degradation. Through a sophisticated series of biochemical assays and molecular analyses, the research team delineated how USP5 interacts with METTL14, an essential component of the N6-methyladenosine (m^6A) RNA methyltransferase complex. This interaction leads to enhanced stability of METTL14, thereby potentiating m^6A modification of target mRNAs implicated in the metabolic machinery of the cell.

m^6A modification, the most prevalent internal mRNA modification in eukaryotic cells, regulates RNA stability, splicing, transport, and translation efficiency. By preserving METTL14 from degradation, USP5 indirectly influences the m^6A epitranscriptomic landscape within FLSs. The study reveals that this epigenetic modification increases the expression of GLUT1, the primary glucose transporter upregulated in RA FLSs, facilitating elevated glucose uptake and glycolytic flux. This axis—USP5 stabilizing METTL14, which enhances m^6A modification and consequently upregulates GLUT1—constitutes a critical driver of the metabolic phenotype seen in RA synoviocytes.

Importantly, the authors provide evidence that disrupting this pathway can attenuate the glycolytic activity of FLSs, offering a potential avenue for therapeutic intervention. In vitro knockdown experiments targeting USP5 resulted in decreased METTL14 protein levels, reduced m^6A modification on GLUT1 mRNA, and diminished GLUT1 expression. This cascade culminated in lowered glucose metabolism and inhibited FLS proliferation and inflammatory cytokine production, underscoring the centrality of the USP5/METTL14/m^6A/GLUT1 axis in RA pathophysiology.

The research team’s meticulous approach extended beyond cellular models. Using synovial tissue samples from RA patients, they confirmed that USP5 and METTL14 expression levels are markedly elevated in inflamed joints compared to healthy controls. Correspondingly, GLUT1 was found to be significantly upregulated, correlating with disease severity and markers of inflammation. These findings highlight the clinical relevance of the identified pathway and posit that targeting USP5 might disrupt the vicious cycle of inflammation and metabolic dysregulation in RA.

From a broader perspective, this study exemplifies the emerging concept that metabolic reprogramming is not merely a consequence but a driver of inflammatory diseases. By elucidating the mechanistic underpinnings of FLS glycolysis control via epitranscriptomic regulation, the investigation bridges the fields of immunometabolism and RNA biology, promising fresh insights into chronic autoimmune disorders. Therapeutic strategies aiming to inhibit USP5 or modulate m^6A methylation might offer more selective and effective disease-modifying agents with potentially fewer systemic side effects than conventional immunosuppressants.

Moreover, the role of deubiquitinating enzymes such as USP5 in controlling m^6A writers adds a new dimension to the intricate post-translational and epigenetic regulation in immune cells and inflamed tissues. The crosstalk between ubiquitination and RNA methylation as unveiled in this study may inspire a wave of research exploring similar mechanisms in other autoimmune or inflammatory contexts. It also opens the door to drug discovery programs focusing on small molecule inhibitors or degraders of USP5, some of which might already be in developmental pipelines owing to the enzyme’s importance in cancer biology.

An intriguing aspect of the findings is how the altered metabolic state of FLSs perpetuates joint inflammation through enhanced production of pro-inflammatory mediators. Increased glycolysis fuels biosynthetic and energy-demanding pathways needed for sustained synovial hyperplasia, pannus formation, and secretion of cytokines such as TNF-α and IL-6. Blocking the metabolic reprogramming cascade might thus concurrently impede both the hyperproliferative behavior of synoviocytes and the inflammatory milieu, presenting a two-pronged strategy against RA’s hallmark features.

Looking forward, further pre-clinical studies employing animal models of RA are warranted to evaluate the therapeutic efficacy and safety of targeting USP5. Additionally, the interplay between this axis and other known RA signaling pathways, including hypoxia-inducible factors and nuclear factor-kappa B, remains to be investigated. Such integrative analyses could refine the understanding of disease networks and identify synergistic targets. The development of biomarkers based on USP5/METTL14 activity or m^6A signatures in synovial fluids might also enhance diagnosis and monitoring of treatment responses.

Overall, the reported research advances a paradigm shift by aligning post-translational regulation, RNA epigenetics, and immunometabolism into a coherent narrative explaining RA pathology. The discovery that USP5 stabilizes METTL14 to promote an m^6A-dependent upregulation of GLUT1-mediated glycolysis illuminates a previously uncharted territory of molecular crosstalk crucial to chronic joint inflammation. Such insights invigorate hope for novel interventions capable of not only halting disease progression but also restoring joint homeostasis and function.

As rheumatoid arthritis continues to impose a heavy burden globally, innovations that decipher the cellular and molecular intricacies of its pathogenesis are urgently needed. This study exemplifies the power of merging cutting-edge molecular biology tools with clinical relevance to uncover disease mechanisms. By targeting the metabolic engine run by USP5 and the METTL14/m^6A pathway, researchers may have unlocked a promising new front in the battle against autoimmune arthritis—one fueled by molecular precision and potential for transformative impact.

Subject of Research: Mechanistic exploration of how USP5 modulates glycolysis in fibroblast-like synoviocytes through stabilizing the METTL14/m^6A/GLUT1 molecular axis in rheumatoid arthritis.

Article Title: USP5 promotes glycolysis of fibroblast-like synoviocytes by stabilizing the METTL14/m^6A/GLUT1 axis in rheumatoid arthritis.

Article References:
Li, X., Ling, M., Wen, Z. et al. USP5 promotes glycolysis of fibroblast-like synoviocytes by stabilizing the METTL14/m^6A/GLUT1 axis in rheumatoid arthritis. Cell Death Discov. (2025). https://doi.org/10.1038/s41420-025-02890-2

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-025-02890-2

The devastation caused by rheumatoid arthritis extends beyond mere joint inflammation; it is a progressive disease characterized by the relentless attack on bone tissue. Osteoclasts, the cells responsible for bone resorption, are overactivated in RA, leading to the destruction of bone structures and permanent disability. Currently available treatments, while effective at controlling symptoms, often fall short of preventing or reversing pre-existing joint damage and come with considerable side effects. This gap in effective treatment has propelled researchers to explore combination therapies that can enhance therapeutic efficacy while mitigating toxicity.

The study led by researchers from the China–Japan Friendship Clinical Medical College investigated the combined effects of TP and Med in a collagen-induced arthritis (CIA) rat model. This model is well-established for mimicking the pathophysiology of human RA and provides a robust platform for evaluating the efficacy of new therapeutic agents. The researchers found that the coadministration of TP and Med alleviated the severity of arthritis symptoms while simultaneously delaying disease onset. Remarkably, the combination therapy demonstrated superior effects in reducing bone erosion when administered at half the individual doses of each agent, highlighting the enhanced power of synergistic therapy.

Detailed analyses through micro-computed tomography (micro-CT) and histological examinations revealed compelling evidence of the treatment’s efficacy. The combination treatment significantly diminished bone surface-to-volume ratios while increasing overall bone volume in critically impacted joints, such as the ankle and knee. Furthermore, secondary assays, including tartrate-resistant acid phosphatase (TRAP) staining and F-actin ring assays, illustrated a profound reduction in both the number and function of osteoclasts. This finding is crucial as it highlights not only the potential of this combination therapy to inhibit bone resorption but also its applicability to clinical scenarios where RA-induced bone destruction is prevalent.

At the molecular level, the study intricately elucidates the mechanisms by which TP and Med exert their therapeutic effects. The researchers identified that both compounds engage with critical components of the m6A methylation pathway, a cellular mechanism that regulates RNA metabolism and has emerged as an essential player in various biological processes, including osteoclastogenesis. TP targets methyltransferase-like 3 (METTL3), which catalyzes the methylation of osteoclast-related mRNAs. Conversely, Med interacts with the YTHDF1 protein, which is responsible for reading and facilitating the translation of these methylated mRNAs. This dual-targeting approach significantly impairs the signaling pathways leading to osteoclast differentiation and activity, marking a pioneering direction in RA treatment.

The validity of these molecular findings was further strengthened through in vitro experiments where primary bone marrow mononuclear cells (BMMs) from mice were utilized. These experiments confirmed that TP and Med inhibited receptor activator of nuclear factor κB ligand (RANKL)-induced osteoclastogenesis in a dose-dependent manner. Moreover, RNA immunoprecipitation assays demonstrated the direct interaction between METTL3 and YTHDF1 with osteoclast-related mRNAs, establishing a clear rationale behind their effectiveness in modulating osteoclast activity.

Another significant aspect of this study is its exploration of the inflammatory response in collagen-induced arthritis. The combination therapy not only reduced levels of pro-inflammatory cytokines, such as interleukin-1 beta (IL-1β) and interleukin-6 (IL-6), but also promoted a replenishment of regulatory T cells (Tregs) in the spleen. Tregs are crucial in maintaining immune balance and tissue homeostasis, articulating a comprehensive immunological improvement resulting from TP and Med treatment. This dual action of alleviating inflammation while preserving bone tissue is particularly noteworthy and suggests a multifaceted therapeutic landscape for RA management.

The overall findings of this groundbreaking study provide a compelling case for the combination of TP and Med as a transformative treatment strategy in rheumatoid arthritis. By effectively targeting the m6A methylation pathway, this therapeutic duo could represent a paradigm shift in the way RA is managed, aiming not only to control symptoms but also to provide long-lasting protection against bone erosion. Furthermore, the potential implications of these findings extend beyond RA, opening up possibilities for similar approaches in other inflammatory and autoimmune diseases characterized by aberrant osteoclast activity.

Future research will undoubtedly need to refine dosing regimens and assess the long-term effects of such combination therapies in larger clinical settings. There is also a critical need to explore the underlying mechanisms in more depth to better understand how these compounds can be optimized for human application. Given the intricate nature of autoimmune diseases, the pursuit of tailored combination therapies offers hope for improved patient outcomes in diseases like RA that have long been challenging to treat satisfactorily.

In conclusion, the integration of triptolide and medicarpin in rheumatoid arthritis therapy illuminates a promising avenue for restoring the delicate balance between inflammation and bone integrity. As the scientific community continues to unravel the complexities of autoimmune diseases, such innovative approaches will undoubtedly usher in new horizons for effective treatment modalities aimed at improving quality of life for those affected.

Subject of Research: Combination Therapy for Rheumatoid Arthritis
Article Title: Increased Alleviation of Bone Destruction in Individuals with Rheumatoid Arthritis via the Coinhibition of the METTL3 and YTHDF1 Axis by the Combination of Triptolide and Medicarpin
News Publication Date: 13-May-2025
Web References: https://doi.org/10.1016/j.eng.2025.03.014
References: Not available
Image Credits: Yi Jiao, Zhaoran Wang, Wenya Diao, Qishun Geng, Xing Wang, Xiaoxue Cao, Tong Shi, Jiahe Xu, Lu Zhao, Zihan Wang, Tiantian Deng, Lei Yang, Tingting Deng, Cheng Xiao

Keywords

Health and medicine